Pressure BioSciences (OTCQB: PBIO) (“PBI”) is a leader in the development and sale of broadly enabling, pressure-based instruments, consumables and specialty testing services to the worldwide nutraceuticals, biotherapeutics and other industries. The company today announced its entry into an agreement with North Star Holdings (“NSH”) on the financial partnership for the development, production, distribution and commercial roll-out of NSH’s novel, effectively water-soluble, nanoemulsified CBD spray for topical use. In addition, PBI will partner with the NSH team on the development and distribution of additional nano-CBD containing products that the highly successful Colorado cannabis operator has already suggested. “John’s years of experience in the cannabis space, his highly successful and vertically-integrated state-wide enterprise, and his company’s rapid growth over the past seven years to nearly $20 million in annual revenue is very impressive,” said Richard T. Schumacher, president and CEO of PBI, speaking of NSH and its president and CEO John Kaweske. “John has already delivered highly valuable perspectives and strategies that we believe will help NSH get their new nano-CBD topical product to market faster and more efficiently than could have happened had we partnered with anyone else. This is a tremendous opportunity for both NSH and PBI, one that we believe will generate several million dollars in annual revenues for PBI in 2023, with exciting, accelerating growth into the future.”
Wall Street Researcher
BREAKOUT ALERT
PRESSURE BIOSCIENCES INC
PBIO OTCQB
Pressure BioSciences Doubles Growth Projections for UST Nanoemulsion Contracts Following Clear Confirmation of Unmet Needs in Exploding Cannabis Drinks Sector
Investor Contact – Gary Zwetchkenbaum- Plum Tree Consulting LLC –Cell : 516 – 455-7662 – EMAIL – gzplumtree@gmail.com
__________________________________________________________
These shares have formed a bottom at current levels . We feel that the 200 day M/A of $2.15 could be tested to the upside soon. Average daily volume is 17,417 shares for the same 200 day period .
A superior management team and a unique technology is driving these shares higher discovering new uses for their medical device – Ultra Shear Tech Platform
We feel that a BUYING OPPORTUNITY is now at hand . All serious investors must place these shares on their BUY LIST and watch carefully for an UPSIDE BREAKOUT – Our Target $3.50
Investor Contact – Gary Zwetchkenbaum- Plum Tree Consulting LLC –Cell : 516 – 455-7662 – EMAIL – gzplumtree@gmail.com
WATCH THIS INVESTOR VIDEO WITH PRESSURE BIOSCIENCE CEO RIC SCHUMACHER
WEBSITE PRODICTS TEAR SHEET SEC FILINGS PRESENTATION
TechTalks Video CEO Presentation – Watch
Pressure BioSciences Doubles Growth Projections for UST Nanoemulsion Contracts Following Clear Confirmation of Unmet Needs in Exploding Cannabis Drinks Sector
Conferences on West Coast and Midwest Illuminate Rapid Market Expansion of Cannabis Beverages and Critical Role for UST Nanoemulsions to Revolutionize Effective Precision Dosing and Delivery
SOUTH EASTON, MA / ACCESSWIRE / August 5, 2022 / Pressure BioSciences, Inc. (OTCQB:PBIO) (“PBI” or the “Company”), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and specialty testing services to the worldwide biopharmaceuticals, nutraceuticals, cosmetics, agrochem, and food/beverage industries, today announced that its participation at the recent San Francisco and Chicago Cannabis Drinks Expos produced over 60 strong leads for prospective contracts serving the cannabis beverages sector. The need for more effective delivery of cannabis dosing quickly and with reliably repeatable precision was a nearly universal theme reinforced across two days of meetings with companies already active in or entering the $2 billion cannabis beverage market. Among these leads, seven companies requested immediate discussions and follow-up on the potential for incorporating PBI’s patented Ultra Shear Technology™ (UST™) platform for the nanoemulsification of CBD and other cannabinoids into their cannabis product lines as quickly as possible.
Mr. Kenneth F. Micciche, PBI’s Director of Business Development, commented: “PBI’s patented UST platform is a unique breakthrough nanoemulsification system designed to resolve one of the most significant problems facing manufacturers of cannabis infused beverages today: the extremely poor solubility of cannabis-derived oils (e.g., CBD) in water. Poor water solubility results in poor bioavailability of the oil-based cannabinoid (CBD, CBG, CBN, THC, etc.), results in unreliable and variable dosing and response times, and deprives the consumer of the ability to enjoy the full benefits of the cannabis active ingredients for which they are paying.”
As with any oil-based product, it is difficult for the water-based biochemistry of humans and other animals to access and absorb active ingredients hidden within oil droplets at the scale delivered by many current “nanoemulsion” technologies. The natural immiscibility of oil and water inhibits effective water solubility and absorption of oil-based components, resulting in poor and unpredictable bioavailability of active ingredients. This makes it exceedingly difficult to design and deliver proper dosing of the desired active ingredients. Scientific data have repeatedly shown that oil-based active ingredients manufactured into high quality nanoemulsions with consistent, low nano-droplet sizes have produced dramatically faster and reliably complete amounts of cannabinoids (and other oil-based active components). This revolution in absorption and bioavailability delivers higher quality and more desirable finished products for the consumer.
Mr. John B. Hollister, Director of Sales and Marketing at PBI, reflected on PBI’s participation in these two cannabis drinks expositions: “With our proven ability to deliver what we believe to be the highest quality nanoemulsions of CBD and other cannabinoids worldwide, we had expected very positive meetings and engagement around UST. Frankly, these two expos vastly exceeded our expectations. The interest in our UST nanoemulsions platform kicked off with inquiries before the exhibits were even open and continued strong throughout each day and into the evening’s activities. We had dozens of visitors to our booth, comprised of a wide variety of beverage manufacturers – including producers of beer, seltzers, soft drinks, juices, energy drinks, and water. Although these visitors were from various parts of the beverage industry, they all had one thing in common – they needed a reliable method to provide fast and accurate dosing of CBD and other cannabinoids for infusion into their drinks.”
Mr. Hollister continued: We identified over 60 booth visitors as highly qualified leads. Some were groups doing substantial business who quickly understood the benefits of the UST process; others were companies about to initiate production; still others were well-funded start-ups. Of these many leads, seven pressed strongly for immediate follow-up, including three who proposed working towards setting up UST nanoemulsion processing for cannabinoids in their own laboratories in 2023.”
Mr. Richard T. Schumacher, President and CEO of PBI, summed up: “This was our first time participating in cannabis-focused expositions – and it was a resounding success! Last month we announced our plan and forecast to have a minimum of six UST nanoemulsion toll-processing contracts in place by the close of 2022. Based on the immediate traction gained in these two cannabis beverage meetings, and the feedback to date from our Consortium colleagues at The Ohio State University focusing on UST introductions and rapid penetration into the Food and Beverages industry, we have increased our guidance to a total of twelve UST contracts to be closed by the end of 2022. We believe that each of these new contracts will offer $1M or more per year in incremental revenue to PBI in 2023 and beyond.”
About Pressure BioSciences, Inc.
Pressure BioSciences, Inc. (OTCQB: PBIO) is a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life sciences and other industries. Our products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or PCT) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to control bio-molecular interactions safely and reproducibly (e.g., cell lysis, biomolecule extraction). Our primary focus is in the development of PCT-based products for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil & plant biology, forensics, and counter-bioterror applications. Additionally, major new market opportunities have emerged in the use of our pressure-based technologies in the following areas: (1) the use of our recently acquired, patented technology from BaroFold, Inc. (the “BaroFold” technology) to allow entry into the bio-pharma contract services sector, and (2) the use of our recently-patented, scalable, high-efficiency, pressure-based Ultra Shear Technology (“UST”) platform to (i) create stable nanoemulsions of otherwise immiscible fluids (e.g.,oils and water) and to (ii) prepare higher quality, homogenized, extended shelf-life or room temperature stable low-acid liquid foods that cannot be effectively preserved using existing non-thermal technologies.
InvestorNewsBreaks – Pressure BioSciences Inc. (PBIO) Enters New Contract Expected to Generate Significant 2023 Revenue, Drive Accelerated Future Growth
Pressure BioSciences Announces Second Contract for Toll Manufacturing of a CBD Nanoemulsion Product Using Its Proprietary Ultra Shear Technology Platform
PBI Partners with Leading Colorado Cannabis Company for Manufacture and Distribution of Novel Nano-CBD Topical Spray and Other Products, Anticipating $2 Million in 2023 Revenue Contribution
SOUTH EASTON, MA / ACCESSWIRE / July 21, 2022 / Pressure BioSciences, Inc. (OTCQB:PBIO) (“PBI” or the “Company”), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and specialty testing services to the worldwide nutraceuticals, biotherapeutics, cosmetics, and food/beverage industries, among others, today announced its agreement signed with North Star Holdings (“NSH”) on their financial partnership for the development, production, distribution and commercial roll-out of NSH’s novel, effectively water-soluble, nanoemulsified CBD spray for topical use. NSH’s roll-out and distribution plan for the nano-CBD topical spray conservatively estimates revenues of approximately $1.5M in 2023. PBI will also partner with the NSH team on the development and distribution of additional nano-CBD containing products that the highly successful Colorado cannabis operator has already suggested. NSH believes it could generate an additional $4.5M in revenue from these nano-CBD containing products in 2023. Under the terms of the contract, PBI expects to receive about one-third of total product revenue. This is the second contract recently announced by PBI for financial partnership in the toll manufacturing and subsequent distribution of non-PBI products, based upon an independent company’s use of nano-CBD generated from PBI’s patented Ultra Shear Technology™ (UST™) processing platform.
North Star Holdings, Inc., founded in 2015 and based in Colorado Springs, is a rapidly growing, vertically-integrated, multi-state enterprise-level cannabis operator in states where medical and/or adult-use cannabis is legal. NSH owns 13 dispensary licenses in Colorado, owns thousands of square feet of cultivation and manufacturing facilities, and has a highly effective network of wholesale and retail product marketing and distribution channels. In 2021, NSH’s revenue topped $18 million.
Mr. John Kaweske, President and CEO of NSH, commented: “The Cannabis Industry now intimately understands that the differentiation of high quality and effective bioavailability for oil-based active ingredients like CBD and other cannabinoids in consumer-friendly clean-label products (without undesirable additives) requires processing into long-term stable, highly water-soluble nanoemulsions that achieve extremely low droplet sizes. I have been in this industry for a decade, distributing a large number of products from all over the U.S. and selling many millions of dollars of cannabinoid products annually. I have detailed, first-hand knowledge of the relative positioning and success of the products in the marketplace. In my experience, there are very few – if any – high-performance products containing true CBD nanoemulsions available in the market today, due to the limitations and compromises implicit in current nanoemulsion production technologies.”
Mr. Kaweske continued: “I am extremely excited to partner with PBI, because their UST-produced nano-CBD is unrivaled in its proven ability to achieve consistent, ultra-low droplet size nanoemulsions that deliver unmatched stability, effective water-solubility, and the resulting benefits expected in dosage control, fast delivery, and bioavailability. I believe the products that NSH will help produce and then market containing UST-processed nano-CBD have great potential to become standard-setters in the markets that we serve.”
Mr. Richard T. Schumacher, President and CEO of PBI, added: “John’s years of experience in the cannabis space, his highly successful and vertically-integrated state-wide enterprise, and his company’s rapid growth over the past seven years to nearly $20 million in annual revenue is very impressive. John has already delivered highly valuable perspectives and strategies that we believe will help NSH get their new nano-CBD topical product to market faster and more efficiently than could have happened had we partnered with anyone else. This is a tremendous opportunity for both NSH and PBI, one that we believe will generate several million dollars in annual revenues for PBI in 2023, with exciting, accelerating growth into the future.”
PBI’s Chairman, Mr. Jeffrey N. Peterson put this in strategic context for PBI: “Emerging from intense multi-year R&D on UST, our team has recently completed a thoughtful 3-year plan for PBI, prioritizing funding and investment to accelerate commercialization of the UST platform. Our early emphasis on toll manufacturing partnerships allows us to participate more deeply in the strategic positioning and differentiation of diverse UST-enabled nanoemulsion products. It also allows PBI to participate in the financial upside of this powerful technology affecting a multitude of multi-billion-dollar markets, spanning nutraceuticals, pharmaceuticals, cosmetics and personal care products, as well as food and beverages, agrochemicals and more. We believe the commercialization of the UST platform offers a revolutionary growth and financial performance breakout for PBI that will result in the achievement of financial breakeven in 2023 and accelerating profitability beyond. We will continue to apprise investors on further contract negotiations being closed and our growth acceleration in the coming days and weeks.”
About Pressure BioSciences, Inc.
Pressure BioSciences, Inc. (OTCQB:PBIO) is a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life sciences and other industries. Our products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or PCT) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to control bio-molecular interactions safely and reproducibly (e.g., cell lysis, biomolecule extraction). Our primary focus is in the development of PCT-based products for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil & plant biology, forensics, and counter-bioterror applications. Additionally, major new market opportunities have emerged in the use of our pressure-based technologies in the following areas: (1) the use of our recently acquired, patented technology from BaroFold, Inc. (the “BaroFold” technology) to allow entry into the bio-pharma contract services sector, and (2) the use of our recently-patented, scalable, high-efficiency, pressure-based Ultra Shear Technology (“UST”) platform to (i) create stable nanoemulsions of otherwise immiscible fluids (e.g.,oils and water) and to (ii) prepare higher quality, homogenized, extended shelf-life or room temperature stable low-acid liquid foods that cannot be effectively preserved using existing non-thermal technologies.
Pressure BioSciences to Expand on Upcoming Release of CBD Nanoemulsion Oral Spray at July 6th Emerging Growth Conference – Annual Revenue to PBI Expected to Exceed $1M
Company Invites Investors, Analysts, and Advisors to Attend Its Real-Time, Interactive Update/Q&A Session
SOUTH EASTON, MA / ACCESSWIRE / July 6, 2022 / Pressure BioSciences, Inc. (OTCQB:PBIO) (“PBI” and the “Company”), a leader in the development and sale of innovative, broadly enabling, pressure-based instruments, consumables, and specialty testing services to the worldwide life sciences, nutraceuticals, cosmetics, food & beverage, and other key industries, today announced the Company’s participation in the July 6th Emerging Growth Investor Conference. This real-time, interactive conference will feature a number of exciting, rapidly-growing publicly traded companies, presenting for 30-45 minutes each. PBI’s President and CEO, Mr. Richard T. Schumacher, will be speaking at 10:30 am ET. Mr. Schumacher will briefly expand on the Company’s recent announcement of its contracted production launch of its first UST-processed commercial product: a nanoemulsified CBD aerosol spray for oral use.
Last week, PBI announced the execution of an agreement with Safer Medical of Montana (“SMM”) covering the production, distribution, commercial roll-out, and financial partnership for a novel, effectively water-soluble, nanoemulsified CBD spray for oral use. SMM’s roll-out and distribution plan targets revenues of $3M or more over the first 12-months post-release. Under this agreement, PBI expects to realize more than $1M in revenue from SMM’s $3M sales target. This is the first commercial product produced and marketed that uses the Company’s patented Ultra Shear Technology™ (UST™) platform.
DATE: Wednesday, July 6, 2022 (10:30 am ET)
PRESENTATION: Video Webcast – Presentation plus Q&A
REGISTER: Click here to register for the conference
Highlights of PBI’s Recent Press Release on the Contracted Production Launch of a UST-Processed, Nanoemulsified CBD Spray for Oral Use – with Estimated Annual Revenue to PBI Expected to Exceed $1,000,000:
- PBI will release its first ever UST-processed product to the U.S. market over the next few months
- This unique product is a long-term stable, highly water-soluble CBD aerosol spray for oral use
- Formulation of the product has been completed: only plant-based reagents are used in the product
- Safer Medical of Montana (SMM) will partner with PBI on production, distribution, commercial roll-out, and financial returns – terms of this partnership are in an agreement that was recently executed by the companies
- SMM has existing distribution channels and infrastructure for its current health and wellness products
- SMM estimates that first-year sales will meet or exceed $3M with revenue of over $1M belonging to PBI
- SMM believes no other CBD oral spray available today can compete with the quality and water absorbability of the PBI UST-processed nanoemulsified product
About EmergingGrowth.com & the Emerging Growth Conference
Founded in 2009, EmergingGrowth.com quickly became a leading, independent small cap media portal. Over the years, it has developed an extensive history of providing unparalleled content in identifying emerging growth companies and markets that can be overlooked by the investment community.
The Emerging Growth Conference has proven to be an effective way for publicly traded companies to present and communicate new products, services, and other major announcements to the investment community in an effective and time efficient manner. The audience includes potentially thousands of individual and institutional investors, as well as investment advisors and analysts.
About Pressure BioSciences, Inc.
Pressure BioSciences, Inc. (OTCQB: PBIO) is a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life sciences and other industries. Our products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or PCT) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to control bio-molecular interactions safely and reproducibly (e.g., cell lysis, biomolecule extraction). Our primary focus is the development of PCT-based products for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil & plant biology, forensics, and counter-bioterror applications. Additionally, major new market opportunities have emerged in the use of our pressure-based technologies in the following areas: (1) the use of our recently acquired, patented technology from BaroFold, Inc. (the “BaroFold” technology) to allow entry into the bio-pharma contract services sector, and (2) the use of our recently-patented, scalable, high-efficiency, pressure-based Ultra Shear Technology (“UST”) platform to (i) create stable nanoemulsions of otherwise immiscible fluids (e.g., oils and water) and to (ii) prepare higher quality, homogenized, extended shelf-life or room temperature stable low-acid liquid foods that cannot be effectively preserved using existing non-thermal technologies.
Forward Looking Statements
This press release contains forward-looking statements. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our or our industry’s actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed, implied, or inferred by these forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “could,” “would,” “expects,” “plans,” “intends,” “anticipates,” “believes,” estimates,” “predicts,” “projects,” “potential” or “continue” or the negative of such terms and other comparable terminology. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. In evaluating these statements, you should specifically consider various factors. Actual events or results may differ materially. These and other factors may cause our actual results to differ materially from any forward-looking statement. These risks, uncertainties, and other factors include, but are not limited to, the risks and uncertainties discussed under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021, and other reports filed by the Company from time to time with the SEC. The Company undertakes no obligation to update any of the information included in this release, except as otherwise required by law.
Neither PSN or WSR nor its owners, members, officers, directors, partners, consultants, nor anyone involved in the publication of this website, is not a registered investment adviser or broker-dealer or associated person with a registered investment adviser or broker-dealer and none of the foregoing make any recommendation that the purchase or sale of securities of any company profiled in the PSN or WSR website is suitable or advisable for any person or that an investment or transaction in such securities will be profitable. The information contained in the PSN or WSR website is not intended to be, and shall not constitute, an offer to sell nor the solicitation of any offer to buy any security. The information presented in the PSN or WSR website is provided for informational purposes only and is not to be treated as advice or a recommendation to make any specific investment. Please consult with an independent investment adviser and qualified investment professional before making an investment decision.. All Reports are reviewed for accuracy and concur that any conclusions made are reasonable expectations. The term Buy List referring to a Watch List and not a recommendation to buy . Each individual has their own risk level and should know their risk level and act accordingly . At wriitng writer owns 2500 shares at an average cost of $2.00